NCT01881048 2026-01-29
Window of Opportunity Study Targeting the Inflammatory Milieu
University of Colorado, Denver
Phase EARLY_PHASE1 Completed
Clinical Trials
3 trialsNCT07104266 2025-08-05
Triple Negative Breast Cancer and Celecoxib. Pilot Study
Université de Sherbrooke
Phase 2 Recruiting
NCT05756166 2025-06-24
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated